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Abstract
Background: Gastrointestinal stromal tumors (GIST), one of the most common mesenchymal tumors of the
gastrointestinal tract, prior to routine immunohistochemical staining and the introduction of tyrosine kinase
inhibitors, were often mistaken for neoplasms of smooth muscle origin such as leiomyomas, leiomyosarcomas or
leiomyoblastomas. Since the advent of imatinib, GIST has been further delineated into adult- (KIT or PDGFRa
mutations) and pediatric- (typified by wild-type GIST/succinate dehydrogenase deficiencies) types. Using varying
gender ratios at age of diagnosis we sought to elucidate prognostic factors for each sub-type and their impact on
overall survival.
Methods: This is a long-term retrospective analysis of a large observational study of an international open cohort
of patients from a GIST research and patient advocacy’s lifetime registry. Demographic and disease-specific data
were voluntarily supplied by its members from May 2000-October 2010; the primary outcome was overall survival.
Associations between survival and prognostic factors were evaluated by univariate Cox proportional hazard
analyses, with backward selection at P < 0.05 used to identify independent factors.
Results: Inflections in gender ratios by age at diagnosis in years delineated two distinct groups: above and below
age 35 at diagnosis. Closer analysis confirmed the above 35 age group as previously reported for adult-type GIST,
typified by mixed primary tumor sites and gender, KIT or PDGFRa mutations, and shorter survival times. The
pediatric group (< age 18 at diagnosis) was also as previously reported with predominantly stomach tumors,
females, wild-type GIST or SDH mutations, and extended survival. “Young adults” however formed a third group
aged 18-35 at diagnosis, and were a clear mix of these two previously reported distinct sub-types.
Conclusions: Pediatric- and adult-type GIST have been previously characterized in clinical settings and these
observations confirm significant prognostic factors for each from a diverse real-world cohort. Additionally, these
findings suggest that extra diligence be taken with “young adults” (aged 18-35 at diagnosis) as pediatric-type GIST
may present well beyond adolescence, particularly as these distinct sub-types have different causes, and
consequently respond differently to treatments.
Background
Gastrointestinal stromal tumors
Gastrointestinal stromal tumors (GISTs) are soft tissue
sarcomas that originate from the interstitial cells of
Cajal (ICC), or from stem cells that can differentiate
towards ICCs and can arise anywhere along the gastro-
intestinal tract (GI), and elsewhere in the abdomen with
a reported incidence of up to 14.5 per million per year
[1]. Primary tumors most commonly occur in the sto-
mach or small intestine, and most frequently metastasize
to the liver or peritoneum [2]. The reported median age
of GIST patients varies from 54 to 67 years [3-6].
KIT and PDGFRa genes code for their respective tyro-
sine kinase receptors, and known mutations result in
constitutive activation driving the proliferation and sur-
vival of GIST tumor cells. KIT mutations occur in about
75-80% of GISTs and about 7% have PDGFRa gene
mutations [5]. KIT and PDGFRa mutations are mutually
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in either KIT or PDGFRa and are commonly referred to
as wild-type GIST.
Cytotoxic chemotherapy is ineffective in GIST, and
prior to the introduction of tyrosine kinase inhibitors, the
prognosis for patients with metastatic disease was poor
with a median OS < 2 years [7]. The prognosis for GIST
changed dramatically after the introduction of effective
targeted treatments beginning with clinical trials for ima-
tinib in 2000, and its subsequent approval for advanced
GIST in 2002; sunitinib was approved for imatinib refrac-
tory/intolerant GIST in 2006; approval for adjuvant ima-
tinib in 2008 (EU, 2009). Imatinib is an oral, small-
molecule tyrosine kinase inhibitor initially developed as a
BCL-ABL inhibitor for chronic myelogenous leukemia.
Imatinib also inhibits KIT and PDGFRa,a n dh a sp r o v e d
to be highly effective for GIST, with approximately 85%
of patients receiving significant clinical benefit [3,4,6].
KIT mutations in GIST occur throughout the gene.
The most common encodes the juxtamembrane domain,
exon 11 (60-70% of all GISTs), followed by the extracel-
lular domain, exon 9 (10-15%), the kinase I domain, exon
13 (2%), and activation loop, exon 17 (1.3%) [3,4,8]. The
mutational status of GISTs has proven to be highly pre-
dictive of response to modern therapies. For first-line
therapy, exon 11 mutants respond well to imatinib, but
KIT exon 9 mutations respond less favorably, and appear
to require a higher dose of imatinib [8]. While there is
much less clinical data, most of the more rare mutations,
KIT exons 13 and 17, and PDGFRa exons 12 and 14, are
sensitive to imatinib in vitro [9]. The most common
PDGFRa mutation (62.6% of PDGFRa mutations [5]),
the exon 18 D842V mutation, is insensitive to imatinib
[9].
GIST survival
Reported survival times for GIST patients have varied
widely depending on the era (pre-imatinib, imatinib era
or during the transition), selection criteria, and the start-
ing point used for measuring survival. Several early
reports from GIST referral centers suggested that 90% or
more of GISTs (thought to be gastrointestinal leiomyo-
sarcomas at the time), would eventually have a recur-
rence, and that most patients would eventually die as a
result [10,11]. For example, Nu and colleagues reported
in 1992 a 5-year survival rate of 28% and a median survi-
val of 29 months [10]. These early reports probably were
influenced by referral bias and represented primarily
advanced/metastatic disease.
Survival for advanced/metastatic GIST in the imatinib
era has been reported for several trials. A phase II trial of
147 GIST patients reported a median OS of 57 months
(B2222 [12]), a phase III trial of 746 US/Canadian
patients had a median OS of 53 months (S0033 [13]), and
a larger phase III trial of 946 European/Australasian
patients described a median OS of 45 months (62005,
[13]).
Overall survival data for GIST patients taking adjuvant
imatinib is limited. In a randomized trial comparing 12
months of adjuvant imatinib versus 36 months of adju-
vant imatinib, patients assigned to 36-months of imatinib
had longer OS (HR = 0.45, 95% CI = 0.22-0.89; P =
0.019) [14]. With a median follow-up of 54 months, 92%
of patients receiving 36 months of adjuvant imatinib
were alive compared to 82% alive for patients receiving
12 months of imatinib. All of these survival times were
calculated from the date of trial entry until death. Other
studies may calculate overall survival from the date of
diagnosis, which can often precede enrollment, poten-
tially leading to prolonged observed survival compared to
other results.
Beginning in 2002, reasonably effective criteria for esti-
mating the risk of recurrence have been developed
[15-18]. Using newer population-based studies, larger
institutional studies, and emerging data from adjuvant
imatinib trials, it is now clear that a significant portion of
GISTs have a low to very low risk of recurrence. For
example, preliminary data from the Z9001 adjuvant ima-
tinib trial reported that 45% of patients enrolled were at
low risk according to the Miettinen criteria of recurrence
[19].
Pediatric and adult GIST
GIST in children is rare and patients under the age 18
account for 1-2% of cases. In addition to GIST, pediatric
patients often develop paragangliomas and/or chondro-
mas. When any two of these three are present, it sup-
ports a diagnosis of Carney’s Triad [20].
The etiologies of adult and pediatric GIST appear to be
different, with adult GISTs being primarily driven by KIT
or PDGFRa mutations. In 2007, Pasini et al. reported in
some familial GIST patients, germline mutations in the
succinate dehydrogenase subunits SDHB, SDHC, and
SDHD [21]; SDH mutations had been previously
reported in patients with familial paraganglioma [22].
SDH subunit A mutations have also recently been impli-
cated in GIST [Pantaleo MA, JNCI 2011; Pantaleo MA,
Am J Surg Pathol 2011][23]. In a series of pediatric and
wild-type patients seen at the National Institute of Health
pediatric & wild-type GIST clinic, 4 of 34 (12%) patients
had germline SDH mutations [24]. Other groups have
since reported a loss of SDHB expression in pediatric
GIST patients even when there was no known mutation
[25,26]. Taken together, these findings suggest that loss
of function of SDH, a tumor suppressor, can be a causa-
tive factor in pediatric GIST.
There are considerable differences between pediatric
GIST and those that occur in adults. Up to 85% of
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under half that number of adult patients are female
(45%) [3,4,6]. Pediatric primary tumors tend to be
multi-focal, with epithelioid histology and occur predo-
minantly in the stomach. Adult GIST primary tumors
however, can originate anywhere along the GI tract and
tend to present singly, with spindle cell histology.
Metastases are common in both types, however, metas-
tases to the lymph nodes are common in pediatric
GIST, but rare in adult GIST [28]. In spite of limited
effectiveness of targeted therapies for pediatric GIST,
extended survival times have been reported [29,30].
Methods
Study design
This report describes a retrospective analysis of a long-
term observational study of overall survival in a large
open-cohort of patients diagnosed with GIST. Subjects
represent the lifetime membership registry of the Life
Raft Group (LRG), an international, internet-based pri-
vate, non-profit (501.c.3) medical research and patient
advocacy organization established to champion GIST
patients and facilitate related research.
Setting and subjects
The LRG registry contains data provided by its members
worldwide, recruited by referrals from attending physicians
or other GIST patients. The majority of members however
were acquired through patient-initiated contacts, following
internet searches or other requests for disease-related
information and assistance. All members had a reported
initial diagnosis of GIST. There were no other criteria for
membership, and no one was excluded owing to age, loca-
tion, confirmation of diagnosis, disease status, or prior or
current treatment regimen or response.
Acquisition of data from members was strictly on a
voluntary basis. All data were collected either using elec-
tronic questionnaires periodically forwarded as reminders
to members, a relative, or caregiver, or through phone
interviews. Demographic data included gender, date and
country of birth and country of treatment. Disease-specific
data included date and disease status at diagnosis, disease
status at last update, primary tumor location, and tumor
mutation data as available. Deaths were most often
reported by family members, many of whom are also Life
Raft Group members. In addition, public death records,
such as the social security death index (SSDI) were
reviewed for members without a recent update.
In addition to disease status at initial diagnosis e.g.,
metastatic/not metastatic, the confidence with which a
report of “not metastatic” was estimated and coded into
the database post hoc.T h o s ew h or e c e n t l ya n dr e g u l a r l y
provided updates were deemed of “high confidence”.
“Low confidence” was attributed to those who rarely, if
ever, provided an update beyond initial registration. The
remainder, those who had provided periodic, but not
necessarily a recent update (within ~6 months prior to
cohort analysis), were considered of “intermediate confi-
dence”. Only those deemed of high confidence are
included in the survival analysis of non-metastatic
patients. Questionnaire responses were reviewed, and the
data were coded, logged, and curated by LRG staff, who
also confirmed all end points, e.g., death event; the pri-
mary outcome measure for this study was overall
survival.
This study was conducted under guidelines consistent
with US and international policies regarding research
involving human subjects. All subjects were informed as
t ot h en a t u r ea n dg o a l so ft h i ss t u d y .S u b j e c t sh a dt h e
right to withdraw participation at any time for any rea-
son. While voluntarily obtained, all data were nonetheless
collected and maintained in adherence to regulations on
data involving human subjects.
Statistical methods
Categorical outcomes were analyzed descriptively and
summarized in terms of frequency tables. Means and
standard deviations were used to summarize all variables
measured on a quantitative scale. The associations
between overall survival and gender, age, primary tumor
location, presence of metastatic or advanced disease at
diagnosis, and mutation status were evaluated by per-
forming univariate Cox proportional hazard analysis.
Backward selection with a P-value cut-off of < 0.05 was
used to identify independent prognostic factors for over-
all survival. The proportional hazard assumption was ver-
ified using plots of the log(-log) survival curves and
Schoenfeld residual plots.
All statistical tests were two sided, and P-values < 0.05
were considered significant. Statistical data analyses were
performed using SAS statistical software (version 9.2,
SAS Institute Inc., Cary, NC). Kaplan-Meier curves were
generated using GraphPad Prism version 5.04 for Win-
dows, GraphPad Software, San Diego California USA,
http://www.graphpad.com. All other calculations were
performed using Microsoft Office Excel 2003.
Results
Patient- and disease-related characteristics
Member data were collected from May, 2000 to October,
2010. As of October 12, 2010, the LRG GIST registry
contained 1233 members. Eighteen members (7 males),
were excluded from the final analysis (4 GIST misdiag-
noses, 14 actively opted out). The final cohort included
1215 patients (51.7% male), with a median age at time of
diagnosis of 52 years (range, 5-92); 312 events (62.5%
male) were recorded. Patients were reported to be from
75 different nations and treated in 48 different countries,
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(75.7%), or treated in (70.0%), the US. Country of origin
and treatment were grouped post hoc by continent or as
unknown (Table 1).
One quarter of all patients (23.5%, 285/1215) reported
advanced or metastatic disease at diagnosis, increasing
to nearly two-thirds (63.2%, 768/1215) by last update.
Those not reporting advanced or metastatic disease at
last update were divided into three groups by confidence
in these data: high (n = 209), intermediate (n = 188), or
low (n = 15). Overall survival by disease status at diag-
nosis could be calculated for 1195 patients.
Primary tumor site location was provided as free text
and grouped post hoc as either stomach, small intestine,
rectum/anus, esophagus, multiple gastrointestinal (mult.
GI), other, or unknown. Nearly all cases in the < 18 at
diagnosis age group (26/28), and all tumors in females
aged < 18 years at diagnosis (21/21) were reported in
the stomach; two males in this youngest age group
reported primary tumors in the small intestine. Gender
differences in primary tumor location became less
evident with increasing age, and older age groups
reported a greater range of primary tumor sites
(Table 2).
Age at diagnosis by gender
A distribution of patients by age at diagnosis and by
gender revealed two distinct populations (Figure 1,
Table 3). Eight-seven percent of the cohort was diag-
nosed > 35 years old (54.2% male), 2.4% were diagnosed
before the age of 18 (25.0% male), the remaining “young
adult” sub-group (10.6%, diagnosed at 18-35 years) dis-
played a gender balance between these other two groups
(34.9% male). There were some patients (n = 31, 2.6%)
for which an age at diagnosis could not be determined
(21 missing date of birth, 12 missing date of diagnosis).
Mutational analysis
Three hundred twenty four patients (26.7%) reported
tumor mutation data. Half (53.6%, 15/28) of patients
aged < 18 and a quarter (25.5%, 261/1022) of those > 35
years reported mutation data, with a “young adult”
Table 1 Patient data by gender
Females Males All patients
Total cohort (N) 587 628 1215
Missing date of birth (n) 9 12 21
Missing date of diagnosis (n) 5 7 12
Median age at diagnosis in years [range] 50.5 [5.4-92.2] 52.6 [10.0-90.0] 51.7 [5.4-92.2]
Median follow-up time in years [range] 4.5 [0-39.5] 5.8 [0-30.6] 5.2 [0-39.5]
Death events (n) 117 195 312
Total survival cohort (n) 578 617 1195
Primary tumor location (n) 523 565 1088
Tumor site, survival (n) 519 556 1075
Disease status at diagnosis (n) 587 628 1215
Disease status, survival analyses (n) 578 617 1195
Confidence in no metastatic/advanced disease report (see methods for description)
High confidence 114 100 214
Intermediate confidence 102 96 198
Low confidence 5 12 17
Report of metastatic/advanced disease 366 420 786
Mutation data (n) 164 161 325
Mutation, survival (n) 164 160 324
Continent of birth (n)
N. America 468 489 957
Europe 69 71 140
Asia 30 43 73
Oceania 79 1 6
S. America 61 0 1 6
Africa 639
Unknown 134
Patients missing a date of birth were not included in analyses based on age at diagnosis (n = 21). Follow-up was calculated from date of diagnosis until date of
last update (or endpoint) in years. Survival cohort and sub-groups includes those patients for which overall survival could be estimated. Continents of birth were
grouped post hoc from reported country of birth
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intermediate rate (38.1%, 48/126). Wild-type (wt) muta-
tions were reported in 10 pediatric female patients, with
2 reports of a mutation within SDH subunit C; there
were 2 wild-type GISTS and 1 KIT exon 11 mutation
(familial) reported in males of this youngest age group
(Table 4). The “young adult” group contained 5-fold
more females than the pediatric group and wild-type
GIST and SDH mutations comprised 56% of this middle
group’s (18-35) mutational reports. However, when gen-
der was considered, wild-type GIST was reported almost
Table 2 Reported primary tumor location by age group
and gender
< 18 18-35 > 35 Total
Primary Tumor Location F M F M F M
Stomach 21 5 47 18 198 210 499
Small intestine 2 25 12 148 204 391
Unknown 4 6 54 50 114
Colon 1 16 16 33
Rectum/anus 2 13 17 32
Large & small intestine 2 5 9 16
Stomach & small intestine 6 5 11
Esophagus & stomach 2 3 6 11
Omentum 4 7 11
Esophagus 1 3 6 10
Peritoneum 1 5 4 10
Other 1 5 3 9
Mesentery 1 2 5 8
Pelvis 1 2 5 8
Liver 1 3 2 6
Retroperitoneal 1 4 5
Pancreas 2 2 4
Spleen 1 2 3
Chest 1 1
Adrenal gland 1 1
Bladder 1 1
Total 21 7 82 44 472 558 1184
Primary tumor sites were provided as free text as listed below in decreasing
order. Care must be taken in the interpretation of these data as reporting of
primary tumor location as a single or unique site can be challenging (see
Limitations). Patients of unknown age at diagnosis were not included (n = 31)
Figure 1 Age at diagnosis by gender. Female gender is known to
be associated with pediatric-type GIST. Using high female to male
ratio as a surrogate marker for pediatric GIST, our data suggests that
pediatric-type GIST occurs with decreasing frequency until about
age 35 (at diagnosis). Also see Table 3.
Table 3 Gender ratio by age at diagnosis
Age group at diagnosis Female Male Gender ratio (F:M)
5-10 5 -
10-15 11 4 2.75
15-20 12 4 3.00
20-25 15 7 2.14
25-30 26 14 1.86
30-35 34 22 1.55
35-40 36 40 0.90
40-45 59 75 0.79
45-50 79 83 0.95
50-55 84 102 0.82
55-60 78 92 0.85
60-65 51 78 0.65
65-70 49 49 1.00
70-75 20 23 0.87
75-80 9 12 0.75
80-85 5 2 2.50
85-90 1 2 0.50
90-95 1 -
N/A 12 19 0.63
Table 4 Mutation by age group and gender
Gene Exon/subunit < 18 18-35 > 35 Total
FMFM F M
KIT 11 1 8 6 71 100 186
93 3 1 8 2 0 4 4
13 2 5 7
Wild-type 10 2 25 12 8 57
PDGFRa 1 8 171 01 8
12 3 2 5
17 1 1
Unknown 1 1
SDH C 2 2
B1 1 2
Unknown 1 1
Unknown 9 4 45 33 352 409 852
Grand Total 21 7 82 44 467 555 1176
Mutational status was reported by nearly one third of the cohort (n = 325).
Patients of unknown age at diagnosis were not included (n = 31). Pediatric-
type mutations include the wild-type GIST and SDH mutations. Wild-type GIST
is a characteristic of pediatric-type GISTs, and 12 of 15 patients aged < 18 at
diagnosis reported wild-type GIST. However, wild-type GIST is a
heterogeneous mix that includes both adults and pediatric patients. KIT and
PDGFRa mutations are broken out by exon, where known, whereas mutations
within the succinate dehydrogenase complex denote subunits
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mutation in a male in this age group. The adult popula-
tion contained a closer balance of genders and muta-
tions, as well as a greater variety of reported mutations
with 8% reporting wild-type GIST (12 females, 8 males)
or SDH mutations (1 female).
Overall survival by gender, age at diagnosis and reported
disease status, tumor site and mutation
Overall survival (OS) could be calculated for 1195 patients
(51.6% male) for which there were a total of 312 recorded
deaths (62.5% male). The median OS for the entire cohort
was observed to be 11.7 years, with a 79% 5-year OS.
When gender was considered, females showed a 4.2 year
median OS benefit over males (P = 0.0012, HR = 1.456,
95% CI = 1.2-1.8; Figure 2) with a median OS of 14.5 years
for females and 10.3 years for males.
When placed into age groups as previously described for
age at diagnosis, the median OS for patients > 35 was 11.3
years, and 15.6 years for those diagnosed 18-35; the med-
ian OS for patients diagnosed < 18 years had not been
reached at time of analysis (P = 0.0004; Figure 3C).
Disease status at time of diagnosis also had a significant
impact upon survival (Figure 4A), with a 6.9 year median
OS observed for patients reporting metastatic or
advanced disease at diagnosis compared to 14.5 years for
those without metastatic/advanced disease at diagnosis
(P < 0.0001, HR = 2.9, 95% CI = 2.2-3.9). The closest
approximation of the registry cohort to the population of
published metastatic trials would exclude all pediatric
patients (< 18 years at diagnosis). When this post-adoles-
cent subgroup was analyzed for survival by report of
advanced/metastatic disease at diagnosis, the median OS
for the all-adult “no mets at diagnosis” group was 13.6
years, however the median OS for those reporting
advanced/metastatic disease at diagnosis was 6.4 years,
~7 fewer years (Figure 4B). Patients > 18 at diagnosis,
and presenting with primary disease only, were divided
into two groups: those who later developed a recurrence
and those who provided recent and regular updates and
never reported a recurrence (median OS was 11.7 years
and undefined respectively, P = < 0.0001, HR = 2.62, 95%
CI = 1.7-4.1, Figure 4C). Patients reporting advanced or
metastatic disease at any time displayed a median OS of
10.3 years.
In contrast to other reports, when wild-type GIST and
SDH patients were combined, their median OS appeared
to be better than other types including those with exon
11 mutations (Figure 5), however both wild-type/SDH
and exon 11 median OS remained undefined. Patients
with exon 9 mutations had a median OS of 10.3 years
and those with PDGFRa mutations had a median OS of
5.7 years, but care should be used in interpreting the
PDGFRa data since only 4 events occurred and median
follow-up time was short (2.7 years) (logrank test for
trend, P ≤ 0.0001, Figure 5).
Factors in overall survival
A Cox-proportional hazards regression model was used
to evaluate the association between reported patient and
disease characteristics and observed overall survival as
calculated from the date of diagnosis. Gender, age at
diagnosis, primary tumor location and report of advanced
or metastatic disease at diagnosis were identified as inde-
pendent significant factors. Male gender was a negative
predictor of survival (male vs. female, HR = 1.5, P =
0.0010). Older age at diagnosis was also a significant pre-
dictor of OS when compared to pediatric patients (> 35
vs. < 18, HR = 8.4, P = 0.0031; 18-35 vs. < 18, HR = 5.8, P
= 0.0167); survival in the “young adult” age group
approached significance compared to the oldest age-
group at diagnosis (> 35 vs. 18-35, HR = 1.4, P = 0.0782).
The report of advanced or metastatic disease at diagnosis
was also significant (present vs. absent, HR = 2.4, P <
0.0001), however while primary tumor location as a fac-
tor was significantly associated with OS, only small
intestinal tumors were found to be significant (small
intestine vs. other HR = 0.7, P = 0.0390).
Discussion
Since the introduction of imatinib in clinical trials in 2000,
and its subsequent FDA approval for KIT-positive GIST in
Figure 2 Overall survival: males vs. females. Females displayed
significantly longer overall survival than males. This appears to be
influenced by the long survival times and greater number of
females in those with pediatric-type GIST. A smaller, but significant
survival advantage was still noted for females > 35 at diagnosis (see
Discussion)
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GIST has been well characterized within controlled clini-
cal settings. Survival of patients without advanced disease,
or otherwise ineligible for trial enrollment has been less
well characterized. This observational registry reports on
the survival of GIST patients at a range of ages, locations,
and disease statuses. Many of these patients participated
in clinical trials, but most did not.
GISTs have been previously divided into two distinct
sub-groups: adult, primarily displaying KIT or PDGFRa
mutations [31,32] and pediatric GIST typified by wild-type
GIST or deficiencies in the succinate dehydrogenase com-
plex [26,30,33]. In our cohort of patients, 2.4% were
diagnosed before the age of 18, 10.6% were diagnosed
between the ages of 18-35, and 87.0% were diagnosed after
the age of 35. The youngest group was dominated by char-
acteristics previously ascribed to pediatric-type GIST:
female (75%; Figure 3A), stomach primary tumors (93%;
Figure 3B), extended survival times (median OS had not
been reached; Figure 3C), and wild-type or SDH mutations
(80% wild-type, 13% SDH mutations; Figure 3D). Patients
in the oldest age-group had characteristics more closely
associated with adult-type GIST: slight male predomi-
nance (54% male), mixed primary tumor locations (37%
stomach), shorter overall survival (median OS = 11.0
years), and dominated by KIT mutations (83%). Patients
Figure 3 Patient and disease characteristics by age group at diagnosis. Patients diagnosed below the age of 18 had characteristics
associated with pediatric-type GIST: female gender (panel A), predominantly stomach primaries (panel B), prolonged overall survival (panel C),
and wild-type GISTor SDH mutations (panel D). Patients diagnosed over age 35 had characteristics associated with adult-type GIST: slight male
preference (panel A), slight preference for stomach primary tumor location followed closely by small intestine primaries (panel B), shorter overall
survival (panel C), and dominated by KIT mutations (panel D). The 18-35 at diagnosis age group had characteristics between those of pediatric-
type and adult GIST. Tumor locations were provided as free text and are depicted as a relative percentage within each age-group (panel B).
Some sites have been grouped post hoc including, multiple GI (stomach and esophagus, stomach and small intestine, small and large intestine),
and “other” which includes all remaining reported primary tumor sites (table 2); the rest were as reported (esophagus, stomach, small intestine,
colon or rectum/anus). This was an attempt to adhere to published groupings without changing the data as reported. Multi GI, colon, and
rectum/anus in the > 35 group, and multi GI in the 18-35 group were ~3% (2.9-3.3%); the remaining unlabelled sites were all < 2% of age-group
(0.8-1.6%).
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mixture of pediatric and adult types, with all four charac-
teristics (gender distribution, primary tumor location,
mutational status and overall survival), falling between
those expected of these previously described GIST types
(Figure 3).
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follow-up, recent/regular updates  
n=205 median OS undefined
P value =<0.0001  
HR=2.623 
Figure 4 Overall survival by disease stage. The effect of disease stage on overall survival for patients > 18 years at diagnosis is shown in
panel A. Patients that had metastatic disease at the time of diagnosis did significantly worse than patients that presented with primary disease
only (panel B). Patients that had a recurrence later still did relatively well, but predictably, not as well as patients without a recurrence (panel C).
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registry was 11.7 years, (14.5 years for females and 10.3
years for males). Females predominated in pediatric-type
GIST and survival is longer in pediatric-type GIST. This
may partially explain the longer survival times of females
when the entire range of ages at diagnosis was consid-
ered; however, females still retained a significant, albeit
smaller, survival advantage even when only patients > 35
years old were considered (median OS = 11.0 years,
females vs. 10.3 years males; P- value = 0.0006, HR =
1.517). Approximately 24% of LRG registry patients
reported metastatic disease at time of diagnosis. This
compares to 11% from a population-based study from
the Rhône Alpes region of France [34], 15% from a popu-
lation-based study in Western Sweden [1], 18% from a
registry of patients from the United States [35], and 30%
from the GOLD reGISTry (Global) [36]. Patients that
initially presented with primary disease only, and later
reported a recurrence, displayed a median overall survival
> 11 years.
The 276 patients diagnosed over the age of 18, and
reporting metastatic GIST at the time of diagnosis, repre-
sent the group of LRG registry patients that is easily
defined, and expected to be most similar to those in the
phase II and III metastatic GIST trials with respect to
overall survival. The median overall survival for this sub-
group within the cohort was 6.4 years from the time of
diagnosis, reflective of the negative impact of metastatic
disease at diagnosis upon overall survival. This is how-
ever, a longer overall survival time than typically reported
for adult patients with metastatic disease, warranting
further investigation. Recently it was reported that overall
survival was better in the SWOG SO33 trial for centers
that treated more than 15 patients versus those that trea-
ted 15 or fewer patients (median OS, 57 months vs 49
months)[37]. An intriguing question is whether patients
receiving treatment or consultations at specialty centers
that see many more GIST patients have better long-term
outcomes than patients receiving care only at commu-
nity- based practices. Another possibility is that approval
of sunitinib in 2006 and off-label treatments such as nilo-
tinib and sorafenib, which are commonly used by mem-
bers (especially from the United States) with advanced
disease, might be impacting overall survival compared to
early trial results for metastatic disease.
The rate of mutational testing within this registry was
26.7% (30.5% for living members). While this is lower
than typical research studies, it is much higher than the
6% testing rate reported in the reGISTry database of 822
patients treated in the United States [34]. The authors
therein noted that the low mutational testing rate
observed could be ascribed to the difference between
actual clinical practice and guideline recommendations
of the National Comprehensive Cancer Network (NCCN)
and European Society of Medical Oncology (ESMO).
They also noted that “Differences in response rates
among reGISTry patients may also be attributed to dif-
ferences in dosing patterns and treatment compliance in
the ‘real-world’ versus clinical trial setting”. The LRG reg-
istry represents a self- reported and international com-
munity, where mutational testing was carried out at a
number of different centers. The level of testing can vary
by center. For example, in the past, some centers tested
for KIT mutations only, whereas testing for any SDH
mutation is relatively rare; The only center within the
United State of which we are aware that routinely screens
for SDH mutations is the National Institutes of Health
(NIH). The level of screening for SDHA mutations,
which have only recently been reported, is unknown. As
reliable immunohistochemical tools for detecting SDH
deficiencies are identified, and become more wide-
spread, we would expect the reported number of cases of
both pediatric-type GIST and those with SDH mutations
to increase.
Although imatinib appears to be less effective in pedia-
tric- than adult-type GIST, relatively long survival times
have been reported for patients with Carney’sT r i a da n d
pediatric GIST [21]. These longer reported survival times
MedianSurvival
Median
FollowͲup
WildͲtype/SDH(n=62) Undefined 5.6yrs
KITexon11(n=186) Undefined 5.4yrs
KITexon9(n=44) 10.3 years 4.5yrs
PDGFRA(n=25) 5.7years 2.7yrs
Logranktestfortrend P=<0.0001 
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Figure 5 Overall Survival by Genotype. When calculated from the
time of diagnosis, patients with wild-type GIST/SDH deficiencies or
KIT exon 11 mutations did better than other types. The long survival
times for wild-type GIST/SDH deficiencies in this series may reflect a
high percentage of pediatric-type GIST patients. The relatively short
survival time noted for PDGFRa mutations should be interpreted
with caution given the small numbers and short follow-up.
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Page 9 of 12pre-date the imatinib era and seem to be related to the
relative indolence of the disease rather than any impact
of imatinib or other targeted therapies. The LRG registry
data confirms these observations for patients diagnosed
below the age of 18. The median overall survival for
these patients has not been reached and is significantly
higher than older patients. In contrast, patients diagnosed
over the age of 35 have shorter survival times in spite of
effective drug therapies. Wild-type GIST/SDH-deficient
patients had longer survival times, possible reflecting a
high percentage of pediatric-type GIST in this group.
In our cohort, the ratio of females to males varied by
the age at diagnosis. In the group of patients diagnosed
below the age of 18, 75% (21/28) were female. The ratio
of females to males remained higher until approximately
age 35 and then dropped precipitously, and inverted
with a slight male predominance in patients diagnosed
after age 35. Adult- and pediatric-type GIST have differ-
ent causes and respond differently to treatments. Pedia-
tric GIST appears to be less dependent on KIT or
PDGFRa than adult GIST, and may be somewhat
dependent on IGF-1R signaling [38], as well as having
deficiencies in the tumor suppressor activity of succinate
dehydrogenase.
Since 2008, the National Institutes of Health, in colla-
boration with the Consortium for Pediatric and Wild-
type GIST Research (CPGR), have been conducting
biannual clinics for patients with wild-type and pediatric
GIST. In addition to providing a resource for these
patients, this group is collecting valuable data on these
GIST subtypes. Given the rarity of pediatric GIST, it is
important that patients and physicians are aware of this
clinic. Our data suggests that, in addition to pediatric and
adolescent patients, a significant portion of diagnosed
“young adults” may also have the pediatric form of GIST.
Pediatric-type GIST in adults was also recently reported
by Rege and colleages in 16 patients (13 women, 3 men),
with a median age at diagnosis of 31.5 years (range 19-
56) [39].
Mutation testing is important for GIST patients includ-
ing those diagnosed below the age of 35. Patients with
characteristics associated with pediatric-type GIST
(female gender, wild-type or SDH mutations, stomach
primary tumors and epitheloid histology), should be
referred to the NIH Pediatric and Wild-type GIST Clinic
whenever possible. Immunohistochemical staining can
also aid in identifying pediatric-type GIST, with a SDHB-
deficiencies being strongly correlated with pediatric-type
GIST [26,33]. All GIST patients diagnosed below the age
of 18 should be referred to the clinic unless they have
documented KIT or PDGFRa mutations. In addition,
patients of any age with wild-type GIST may be eligible
to participate in the clinic.
Limitations
In this study we report on the survival of a large hetero-
geneous group of GIST patients of all ages that includes
both metastatic and primary tumors. While patients in
the LRG registry comprise a diverse group, there are dif-
ferences when compared to the entire GIST population
worldwide. LRG members are self-referred and partici-
pation is via the internet which could be prone to inclu-
sion biases. For instance, younger patients are more
likely to be internet-savvy than older patients, and
patients in less developed co u n t r i e sm a yb ee x c l u d e d
due to a lack of internet access, and other socioeco-
nomic and language barriers. In addition, patients with
advanced disease may be more motivated to participate
than patients with less advanced disease. Being by and
large self-referred, patients in the LRG registry may be
more proactive, more likely to seek treatment at GIST
referral centers, and more likely to register for, and
potentially participate in, controlled clinical trials. In
addition, a higher percentage of LRG patients have
mutational testing (30.6% of living patients) compared
to either those treated by academic centers (12%) or at
community-based practices (1%) in the United States
[35].
Patient-reported primary tumor locations should be
interpreted with caution. In some cases, primary tumors
may be adjacent, or adhered to other organs making
reporting of a single, unique site difficult. For example,
a doctor may report that the (primary) tumor was
attached to the stomach, small intestine and pancreas.
In most cases, operative notes and similar reports were
not reviewed and in some cases primary tumor location
cannot be conclusively determined even when these
documents have been made available.
Conclusions
Pediatric- and adult-type GIST have been previously
characterized in clinical settings and the results of this
long-term observational study of a self-reporting registry
of patients confirm a number of significant prognostic
factors for each from a large, diverse real-world cohort.
Additionally, the convergence of these findings suggest
t h a te x t r ad i l i g e n c eb et a k e nw i t h“young adults” as
pediatric-type GIST may present well beyond adoles-
cence, particularly as these distinct sub-types have dif-
ferent causes, and consequently respond differently to
treatments.
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